Pluri Inc. ($PLUR) is a biotech scaling human, plant and animal cells via its proprietary 3D cell expansion platform, backed by an industrial-scale GMP manufacturing facility. The company has filed fo

The platform targets two markets: Human Health and Longevity, and Foodtech and Bio-Farming — enabling scalable, cost-efficient, reproducible cell expansion for products, services and therapeutics. Proceeds are earmarked for corporate development, working capital and general purposes. Risks are steep: the investment is highly speculative and could result in loss of the entire investment. Add platform, clinical trial and regulatory approval risk, plus uncertainty around financial condition and results. Bottom line: a speculative cell-manufacturing play entering a biotech IPO market that has been deeply sluggish. Size your conviction accordingly.

The platform targets two markets: Human Health and Longevity, and Foodtech and Bio-Farming — enabling scalable, cost-efficient, reproducible cell expansion for products, services and therapeutics.